Company profile: Arcturus Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage mRNA medicines and vaccines, including ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved for use in adults; investigational therapies ARCT-032 and LUNAR-CF for cystic fibrosis and LUNAR-OTC for ornithine transcarbamylase deficiency; and platforms STARR™ mRNA Technology and LUNAR® lipid-mediated delivery for nucleic acid drug delivery.
Products and services
- STARR™ mRNA Technology: Arcturus architects a modular platform combining self-replicating RNA with LUNAR® delivery to produce proteins in vivo for therapeutic or preventive uses across mRNA medicines and vaccines
- LUNAR® Lipid-Mediated Delivery: Arcturus engineers a lipid-based system using proprietary lipids to deliver diverse nucleic acid medicines, including mRNA and siRNA, enabling versatile payload transport for therapeutic applications
- ARCT-154: Arcturus produces a regulatory-approved self-amplifying mRNA COVID-19 vaccine for adults, demonstrating superior immunogenicity against variants
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arcturus Therapeutics
Fogale Nanotech
HQ: France
Website
- Description: Provider of inspection and metrology tools, and process control and characterization solutions for MEMS and semiconductor manufacturers and labs. Offerings include sensing solutions for advanced performance and reliability in harsh environments, medical human-machine interaction systems focusing on ergonomics and surgical room safety, metrological instrumentation for industrial, scientific research, nuclear and defense markets, and blade health monitoring systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fogale Nanotech company profile →
Minus Nine Technologies
HQ: United States
Website
- Description: Provider of UV/EB technologies and products for the graphic arts market, including renewable-content, cationic, and LED-curable solutions; also manufacturing products for industrial applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minus Nine Technologies company profile →
NanoMech
HQ: United States
Website
- Description: Provider of application-specific nanoparticle additives, nanoparticle-based coatings, and coating deposition systems. Founded in 2002, NanoMech creates advanced engineering materials through patent and patent-pending nano-inspired and nano-manufactured product development, applying nano-engineered innovations to machining and manufacturing, lubrication, and energy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoMech company profile →
Genia Technologies
HQ: United States
Website
- Description: Provider of biotechnology leveraging biological nanopores for structure-based sequencing of single DNA molecules, aiming to reduce the price of genome sequencing toward the $100 genome and bring sequencing out of the lab into everyday use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genia Technologies company profile →
Sila
HQ: United States
Website
- Description: Provider of nano-composite silicon anode materials for lithium-ion batteries, including Titan Silicon, delivering up to 20% higher energy density and fast-charge compatibility without compromising cycle life or safety. Collaborates with consumer electronics and automotive OEMs and partners with battery manufacturers; scaling manufacturing capacity to 150 GWh.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sila company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arcturus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arcturus Therapeutics
2.2 - Growth funds investing in similar companies to Arcturus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arcturus Therapeutics
4.2 - Public trading comparable groups for Arcturus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →